L3VLUP
ProSign in

IRON · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IRONJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IRON
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIRONJNJ
Q3 2020none listed holders, n.a.30 holders, $26.2bn
Q4 2020none listed holders, n.a.32 holders, $26.6bn
Q1 2021none listed holders, n.a.31 holders, $25.3bn
Q2 2021none listed holders, n.a.37 holders, $25.6bn
Q3 2021none listed holders, n.a.40 holders, $24.1bn
Q4 2021none listed holders, n.a.33 holders, $25.2bn
Q1 2022none listed holders, n.a.35 holders, $28.2bn
Q2 2022none listed holders, n.a.33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 20232 holders, $7.0m38 holders, $25.0bn
Q3 20231 holders, $2.0m37 holders, $18.9bn
Q4 20232 holders, $29m31 holders, $19.0bn
Q1 20242 holders, $39m32 holders, $19.7bn
Q2 20244 holders, $52m35 holders, $20.4bn
Q3 20245 holders, $102m28 holders, $22.3bn
Q4 20243 holders, $104m37 holders, $20.4bn
Q1 20253 holders, $216m32 holders, $20.5bn
Q2 20252 holders, $128m31 holders, $18.4bn
Q3 20252 holders, $64m32 holders, $23.7bn
Q4 20253 holders, $85m29 holders, $27.8bn
Q1 20263 holders, $69m34 holders, $35.6bn
Q2 20264 holders, $205m33 holders, $39.1bn
IRON

Disc Medicine Inc

Holders
3
Reported value
$104m
Buyers
3
Sellers
1

Breadth +2 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
37
Reported value
$20.4bn
Buyers
23
Sellers
12

Breadth +11 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 38 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IRON (1)

PDT Partners LLC

Only JNJ (35)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, and 10 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →